The deck opens with a title slide for Merck's presentation at the JP Morgan Healthcare Conference, followed by a Business and Pipeline Update delivered by the Chairman and Chief Executive Officer, and a forward-looking statement disclaimer. It then moves through the company's business development activity, its 2025 approvals and trial milestones across oncology, cardiometabolic, infectious disease and animal health, and launch revenue for newer products. Next it sizes the commercial opportunity from new growth drivers against consensus KEYTRUDA sales, and walks through ten key programs and additional pipeline programs. A timeline slide lays out upcoming Phase 3 readouts through 2027. The closing section summarises the strategic priorities, followed by a Q&A slide and an appendix with updated opportunity estimates by therapeutic area and an acronym list. Slides 11, 12 and 19 are worth studying for how large numbers and pipeline categories are presented as simple visual comparisons.
Slides worth studying



Questions about this deck
How many slides does the Merck & Co., Inc. JP Morgan Healthcare Conference presentation have?
The Merck & Co., Inc. deck has 22 slides. Slide 22 is the final slide, an acronym list that defines the abbreviations used in the presentation.
What does the Merck & Co., Inc. deck say about the commercial opportunity from its new growth drivers?
Slide 4 says the commercial opportunity from new growth drivers increased to >$70B, which is non-risk adjusted annual sales by the mid 2030s. Slide 11 compares this with consensus 2028 total KEYTRUDA sales of ~$35B, showing the new growth driver opportunity is more than double that figure.
What does the Merck & Co., Inc. deck say about its ongoing Phase 3 studies?
Slide 4 states that Merck & Co., Inc. has ~80 Phase 3 studies ongoing under its Advancing Diverse & Expansive Pipeline heading. The same slide says the company expects more than 20 new launches, almost all of which have blockbuster potential.
What does the Merck & Co., Inc. deck say about the timing of upcoming Phase 3 readouts?
Slide 16 says the company is anticipating multiple impactful Phase 3 readouts through 2027. Slide 14 lists 2026 readouts, including ISLEND-1 and ISLEND-2 with a PCD of Apr 2026 for islatravir and lenacapavir.
Details
- Company: Merck & Co., Inc.
- Year: 2026
- Type: Conference talk
- Industry: Pharmaceuticals
- Pages: 22
Review score: 7 out of 10, Effective
Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.
The deck has a clear route: milestones, launches, business development, the opportunity sizing on slides 11 to 13, then readouts and priorities. Action titles are mostly assertive, and the identity is consistent with navy header bands, a teal palette and a logo on each page. The key charts on slides 11 and 13 are clear. Weaknesses are consequential: slide 14 leaves the right third empty, slides 6 and 7 grey out earlier columns while stacking small text, slide 19 uses pale text on pale fills (yellow, light blue), and slides 20 and 21 have very small labels that will not read in a room. Slide 18 is an empty appendix divider, and slide 3 is a dense wall of legal text, which is expected here.
Worth keeping: Keep the slide 11 bar comparison with its >2X bracket and large figures, the stacked build on slide 13, and the consistent navy title band and logo system.
Most useful repair: Fill or rebalance the empty right side of slide 14, raise contrast on the pale labels on slide 19, and enlarge text on the slide 21 timeline and the slide 12 program grid.
What would change the score: I would split the slide 21 timeline across two pages and trim the cumulative greyed-out lists on slides 6 and 7 so each page shows one clear set of milestones.
Confidence high. 22 of 22 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-08. Model-assisted review (claude-sonnet-5-5).
Full text of the slides (22 slides)
Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.
Slide 1
JP Morgan
Healthcare
Conference
Merck & Co., Inc., Rahway, N.J., USA
January 12, 2026
Visuals: 1) Logo: a four-lobed teal mark (two stacked pairs of rounded lobes with a white horizontal split through the centre), solid teal about #00857C, top-left corner. 2) Photograph, right half, boxed (not full-bleed; it stops at 88.9% of the height, with a white strip below it): a laboratory scene. In the foreground on the right, a young woman with dark hair pulled back under a grey headband wears clear safety glasses with dark temples and a white lab coat; she looks down at a stainless-steel circular flange or vessel fitting, and her hands in purple nitrile gloves hold it. A clear plastic tube runs over the top of the fitting and a white connector sits at its side. Behind her, out of focus, a smiling man in a white coat and clear glasses is also leaning in. A small patch on her coat shows a teal logo with a blue outline. Lighting is soft and even, from the front and above, with a neutral white-grey background. Dominant colours: silver-grey, white, violet purple (gloves), teal (patch). The framing is medium close-up, cropped at the edges, with the woman's face in the upper-right third.
Slide 2
Business and / Pipeline Update / Rob Davis / Chairman and Chief Executive Officer / 2
Visuals: One photograph, a head-and-shoulders studio portrait of a bald, smiling man with rectangular black-framed glasses, a short greyish-blond moustache and a grey-white goatee. He wears a dark navy suit with a subtle check, a light blue collared shirt and a purple, pink and blue patterned tie. The subject is centred slightly right of the box, facing the camera with head tilted slightly. Framing is tight: head and upper chest fill the box, with the bottom cropped by the box edge at about 93.1% of slide height. Lighting is soft and even studio light from the front, with a gentle falloff to the grey backdrop. Dominant colours are mid grey background (about #8A8A8A fading to #5E5E5E at the edges), navy suit (about #1F2A44), skin tones (about #D9A08A), and purple tie (about #6B3C8C). The photo is boxed, not full-bleed, with no overlay or tint and no rounded corners. A small teal four-lobed logo mark sits in the bottom right footer, about #00857C, with no other logos or icons.
Slide 3
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA / This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the / safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and / expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to / pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If / underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the / forward-looking statements. / Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including / interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the / United States and internationally; global trends toward health care cost containment; technological advances, new products and patents / attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to / accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign / risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, / including patent litigation, and/or regulatory actions. / The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future / events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements / can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the / Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). / 3
Visuals: None apart from a small teal four-lobed logo mark in the bottom-right corner (Merck-style mark). No charts, photographs, tables or diagrams.
Slide 4
Transforming our / portfolio with next / wave of innovation
Advancing Diverse & Expansive Pipeline
~80 Phase 3 studies ongoing
Launching New Growth Drivers
Expect >20 new launches, almost all of which have / blockbuster potential
Executing Business Development
Actively pursuing additional science-driven, / value-creating transactions
Significant commercial opportunity
Commercial opportunity from new growth / drivers increased to >$70B¹, reflecting / substantial progress
1. Non-risk adjusted annual sales by the mid 2030s
4
Visuals: Photograph (left column, x 0 to 42.5%, y 40.4 to 100%, full-bleed to the slide edges at left and bottom): a modern glass-and-brick office building seen from a low angle, with stacked rows of tinted windows, a brick band, a white rooftop canopy at upper right and a pale grey tower behind it. A large translucent white cut-out graphic in the form of a stylised rounded shape (a circular or lobed mark) overlays the facade, cropping across the windows at left. In the lower centre a construction site with cranes and scaffolding is visible, with green trees in the foreground at the bottom. Lighting is soft overcast daylight with a hazy, cool atmosphere; dominant colours are pale sky grey, muted teal-green foliage, brick red and blue-grey glass. Composition is a vertical-leaning frame cropped at the slide edges, with no border. Four circular icons, each a filled navy (#0C2340) circle about 7.1% wide and 12.6% tall, with a white line-art pictogram inside: (1) at top, a scientist figure in a lab coat holding a flask with small bubbles above (about 4.8% by 8.5%, a placed image); (2) a rocket launching diagonally up-right with motion lines below-left; (3) two hands clasping in a handshake. The fourth circle is filled teal (#00857C) and contains a white line-art bar chart of five ascending bars with an upward trend arrow above. Divider: a thin light grey horizontal hairline (about 1 px, #C8CDD3) running from about x 45.6% to 95.2% at y 60.4%, interrupted at centre by a downward grey chevron (stroke about 3 px, #9EA7B3, about 5% wide and 4.5% tall) at about x 68.3 to 73.2%, y 58.2 to 62.6%. Logo: a small teal (#00857C) four-lobed knot-shaped mark in the bottom right corner, about 3.1% wide and 6.6% tall.
Slide 5
Achieved notable clinical and regulatory milestones in 2025
Significant Approvals
Oncology
• KEYTRUDA QLEX1
• KEYTRUDA in earlier-stage cancers
• Cisplatin-ineligible MIBC (KEYNOTE-905 2)
• Resectable LA HNSCC (KEYNOTE-689)
Cardiometabolic
• WINREVAIR PAH label update (ZENITH)
Infectious Disease
• ENFLONSIA for RSV
Animal Health
• BRAVECTO QUANTUM
• NUMELVI (EU)
1. MK-3475A marketed in the EU as KEYTRUDA SC 2. KEYNOTE-905 was conducted in collaboration with Pfizer and Astellas
5
Visuals: Logo: one teal (#00857C) four-lobed clover-style logo at bottom right. Two or more mint (#E2F5F0) highlight bars sit behind the bullet lines KEYTRUDA QLEX, ENFLONSIA for RSV and NUMELVI (EU). No charts, photographs or diagrams.
Slide 6
Achieved notable clinical and regulatory milestones in 2025 / Significant Approvals / Oncology / KEYTRUDA QLEX¹ / KEYTRUDA in earlier-stage cancers / Cisplatin-ineligible MIBC (KEYNOTE-905²) / Resectable LA HNSCC (KEYNOTE-689) / Cardiometabolic / WINREVAIR PAH label update (ZENITH) / Infectious Disease / ENFLONSIA for RSV / Animal Health / BRAVECTO QUANTUM / NUMELVI (EU) / Key Positive Data Readouts / Oncology / KEYTRUDA / PROC (KEYNOTE-B96) / MIBC (KEYNOTE-B15) / WELIREG / Adjuvant RCC (LITESPARK-022) / 2L+ RCC (LITESPARK-011) / Cardiometabolic / Enlicitide (CORALreef Lipids, HeFH, AddOn) / WINREVAIR (HYPERION, CADENCE) / Infectious Disease / MK-8527 for HIV PrEP / Islatravir-based regimens³ for HIV treatment / 1. MK-3475A marketed in the EU as KEYTRUDA SC 2. KEYNOTE-905 was conducted in collaboration with Pfizer and Astellas / 3. Includes islatravir in combination with doravirine and in combination with lenacapavir / 6
Visuals: none. The only graphic is a small teal four-lobed logo mark at bottom right (about x 91.8, y 92.8, 3.1 by 6.6%), with a dotted grey vertical divider line and two short coloured rules above the column headings. No charts, photographs or diagrams.
Slide 7
Achieved notable clinical and regulatory milestones in 2025
Significant Approvals
Key Positive Data Readouts
Select Trial Initiations
Oncology
KEYTRUDA QLEX1
KEYTRUDA in earlier-stage cancers
Cisplatin-ineligible MIBC (KEYNOTE-9052)
Resectable LA HNSCC (KEYNOTE-689)
Cardiometabolic
WINREVAIR PAH label update (ZENITH)
Infectious Disease
ENFLONSIA for RSV
Animal Health
BRAVECTO QUANTUM
NUMELVI (EU)
Oncology
KEYTRUDA
PROC (KEYNOTE-B96)
MIBC (KEYNOTE-B15)
WELIREG
Adjuvant RCC (LITESPARK-022)
2L+ RCC (LITESPARK-011)
Cardiometabolic
Enlicitide (CORALreef Lipids, HeFH, AddOn)
WINREVAIR (HYPERION, CADENCE)
Infectious Disease
MK-8527 for HIV PrEP
Islatravir-based regimens3 for HIV treatment
Oncology
Phase 3 studies for sac-TMT4 (TROP2) in multiple cancers
Phase 3 studies for calderasib (KRAS G12C) in NSCLC and CRC
Phase 3 studies for I-DXd5 (B7H3) in esophageal and mCRPC
Phase 3 study for P-DXd5 (HER3) in breast cancer
Infectious Disease
Phase 3 studies for MK-8527 for HIV PrEP
Phase 3 study for V181 for dengue
Immunology
Phase 2b studies for tulisokibart (TL1A) in multiple indications beyond IBD
Ophthalmology
Phase 2 study for MK-8748 (Tie-2/VEGF) in NVAMD, DME, and BRVO
Phase 2 study for MK-3000 (Wnt) in NVAMD and BRVO
1. MK-3475A marketed in the EU as KEYTRUDA SC 2. KEYNOTE-905 was conducted in collaboration with Pfizer and Astellas
3. Includes islatravir in combination with doravirine and in combination with lenacapavir 4. In collaboration with Kelun Biotech
5. In collaboration with Daiichi Sankyo
7
Visuals: Left and middle columns (Significant Approvals and Key Positive Data Readouts) are covered by a 75% opaque white overlay that fades their text to pale grey and pale tints. The right column is not covered and shows full-strength navy and blue text. Three light blue (#E1F1FD) highlight rectangles sit behind the highlighted right-column items (sac-TMT at y 32.1, tulisokibart at y 70.4, and the two Ophthalmology items at y 80.5 to 93.7). Column header rules across the top of each column (estimated: teal #B3DDD9 at left, pale lavender #DCE3F8 in the middle, and a thicker blue #1590F3 at right) and faint dotted vertical dividers (estimated light grey #D0D5DD) at about x 30% and x 58.7%. A small teal logo at bottom right (a four-lobed green icon, #00857C).
Slide 8
Accelerating contributions from new product launches
Key launch products
Launch product revenue ($ millions)
$900
$0
$70
$203
$287
$458
$568
$824
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
OHTUVAYRE sales reported by Verona Pharma
WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg
Ohtuvayre (ensifentrine) Inhalation Suspension 3 mg/2.5 mL
CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine
ENFLONSIA (clesrovimab-cfor) 105 mg injection
KEYTRUDA Qlex pembrolizumab + berahyaluronidase alfa-pmph Subcutaneous Injection | 165 mg + 2,000 units/mL
8
Visuals: Five product logos stacked in a two-column grid on the left: WINREVAIR (sotatercept-csrk) top-left, Ohtuvayre (ensifentrine) top-right, CAPVAXIVE top-left below, ENFLONSIA (clesrovimab-cfor) right of it, and KEYTRUDA Qlex full-width-ish below. Each is a flat logo image on white. Right side: one bar chart (embedded as an image, 1100 by 679 px) titled Launch product revenue ($ millions). Type: vertical column chart with solid teal bars and dashed teal outline boxes stacked above some bars. Y axis: $0 to $900, labelled at $0 and $900 with tick marks; the axis is linear in $ millions. X axis: quarters Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025. Printed total labels above each bar: $70 (Q2 2024), $203 (Q3 2024), $287 (Q4 2024), $458 (Q1 2025), $568 (Q2 2025), $824 (Q3 2025). Solid teal segment values are not printed; estimated: Q2 2024 about $70, Q3 2024 about $200, Q4 2024 about $250, Q1 2025 about $390, Q2 2025 about $465, Q3 2025 about $690. Dashed outlined segment (top of bar) is the OHTUVAYRE sales reported by Verona Pharma, shown as the difference between the solid bar and the printed total; roughly $9 at Q3 2024, about $37 at Q4 2024, about $77 at Q1 2025, about $103 at Q2 2025, about $134 at Q3 2025 (estimates). Legend below the x axis: small dashed teal-outlined rectangle followed by 'OHTUVAYRE sales reported by Verona Pharma'. No highlighted points beyond the dashed segments. Bars are flat with no gradients or shadows.
Slide 9
Augmented our pipeline and portfolio with science-driven business development
Select 2025 transactions
OHTUVAYRE
First-in-class PDE 3/4 inhibitor for maintenance treatment of certain patients with COPD
MK-1406
(formerly CD388)
1
Potential first-in-class, once per season, strain agnostic anti-viral to help protect at-risk individuals from influenza
MK-7262
Oral small molecule Lp(a) inhibitor
1. Cidara Therapeutics acquisition closed in January 2026
9
Visuals: Three pharmaceutical company logos and one corporate logo. (1) Verona Pharma logo: a crimson #C8102E-like wordmark 'Verona Pharma' with a registered mark, with a navy #1F2A6B starburst (radiating thin lines with a small centre dot and dashes) above the right end of the wordmark; boxed on white, no crop. (2) Cidara Therapeutics logo: a cluster of about twelve filled circles in teal #2A7F9E and burnt orange #D9622B arranged in an irregular dot cluster to the left, followed by the word 'CIDARA' in teal #2A7F9E large sans-serif capitals and 'THERAPEUTICS' below in widely letter-spaced grey #5A5F66 capitals; a superscript '1' sits to its upper right. (3) Hengrui logo: a dark blue #1A4A9A ellipse containing stylised white slanted strokes and a small yellow-orange capsule shape at upper left, with a white notch at upper right; 'HENGRUI' in blue #1A4A9A capitals below. (4) A small teal #00857C four-lobed flower or clover-like mark at bottom right. No photographs, charts or diagrams. A thin teal #00857C horizontal rule spans the top of the content area.
Slide 10
Augmented our pipeline and portfolio with science-driven business / development
Select 2025 transactions
Strong track record with >$60B / invested since 2021 2
Verona Pharma®
CIDARA THERAPEUTICS
1
OHTUVAYRE
First-in-class PDE 3/4 / inhibitor for maintenance / treatment of certain patients / with COPD
MK-1406 / (formerly CD388)
Potential first-in-class, once / per season, strain agnostic / anti-viral to help protect at- / risk individuals from influenza
HENGRUI
MK-7262
Oral small molecule / Lp(a) inhibitor
ACCELERON PHARMA
Prometheus Biosciences
Daiichi-Sankyo
EyeBio
KELUN-BIOTECH 科伦博泰
HANSOH PHARMA
LaNova Medicines 礼新医药
moderna
CURON
IMAGO BIOSCIENCES
Elanco Aqua
HARPOON Therapeutics
GILEAD
ORION
1. Cidara Therapeutics acquisition closed in January 2026 2. Includes upfront and milestone payments related to acquisitions, strategic collaborations and licensing agreements, select BD transactions shown on slide
10
Visuals: Logos and icons, arranged as in the slide. Left column: Verona Pharma wordmark in magenta with a blue starburst sunburst graphic above its right end; Cidara Therapeutics logo with a cluster of teal, blue and orange-red dots to the left of the CIDARA wordmark in blue-grey and THERAPEUTICS in spaced capitals beneath; Hengrui logo, a dark blue oval with a yellow and white stylised emblem above the HENGRUI wordmark in dark blue. Right column logo grid, row by row: Acceleron Pharma (blue streaks with ACCELERON wordmark in dark navy and PHARMA beneath); Prometheus Biosciences (dark blue wordmark, Biosciences in blue beneath); Daiichi-Sankyo (blue and green circular emblem with Daiichi-Sankyo wordmark in dark blue); EyeBio (pink-purple starburst with EyeBio wordmark in black); Kelun-Biotech (red-and-blue circular emblem with KELUN-BIOTECH in dark blue and Chinese characters); Hansoh Pharma (teal hexagon with yellow emblem and HANSOH wordmark in dark grey); LaNova Medicines (Chinese characters in blue with LaNova Medicines in green); moderna (red lowercase wordmark with blue dashed underline); Curon (dark blue and teal swoosh with CURON in blue); Imago BioSciences (IMAGO in grey, blue dotted-sphere emblem, BIOSCIENCES in grey); Elanco Aqua (blue wordmark with Aqua beneath); Harpoon Therapeutics (dark grey HARPOON with Therapeutics beneath and a blue swoosh); Gilead (red shield-like emblem with GILEAD in grey); Orion (blue arc with ORION in dark blue). Bottom right: small teal-green circular company mark of four lobes. No photographs or charts; all logos are flat, on white.
Slide 11
Commercial opportunity from new growth drivers is more than double consensus 2028 total KEYTRUDA sales
>2X
>$70B
+$20B
opportunity since last year
~$35B
Consensus 2028
total KEYTRUDA sales1,2
Mid-2030s revenue opportunity from potential new growth drivers3
1. Total KEYTRUDA sales include KEYTRUDA and KEYTRUDA QLEX 2. Source: Evaluate Pharma consensus estimate as of January 2026 3. Non-risk adjusted annual sales by the mid 2030s
11
Visuals: Bar chart with a bracketed comparison, no axes or gridlines. Bar 1 (left): solid navy #0C2340 column labelled ~$35B above it, category label 'Consensus 2028 total KEYTRUDA sales' with superscript 1,2 beneath. Bar 2 (right): stacked column, bottom segment dark teal #008477 and top segment mint #6ECEB2 (the top segment is the new opportunity), total label >$70B above; the mint segment is marked with a mint right-facing brace and the callout '+$20B opportunity since last year'. The bars are about equal in width; the right bar is about 1.5 times the height of the left bar, with values printed and no scale. A navy outlined oval containing '>2X' sits on an elbow connector: a horizontal navy line leaves the oval to the left, turns down to the top of the ~$35B label; a second line leaves the oval to the right, runs to the right and turns down with a filled navy arrowhead pointing at the >$70B label. Horizontal navy baseline with three small downward ticks at the left edge, centre and right end of the category area.
Slide 12
Ten key programs represent 70% of >$70 billion commercial opportunity and will potentially transform our portfolio / >$70B / WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg / MK-1406 / ifinatamab deruxtecan3 / Ohtuvayre (ensifentrine) Inhalation Suspension 3 mg/2.5 mL / islatravir based QW regimens2 / sacituzumab tirumotecan4 / enlicitide decanoate / ENFLONSIA (clesrovimab-cfor) 105 mg injection / tulisokibart / MK-3000 / ~70% / Mid 2030s revenue opportunity from potential new growth drivers1 / Oncology / Cardiometabolic & Respiratory / Infectious Disease / Immunology / Ophthalmology / 1. Non-risk adjusted annual sales by the mid 2030s 2. In collaboration with Gilead 3. In collaboration with Daiichi Sankyo 4. In collaboration with Kelun Biotech / 12
Visuals: Stacked bar chart (single column, no axes, no gridlines) with a thin horizontal baseline. Bar top label '>$70B' in bold navy. Bar spans about x 11% to 26% and y 16% to 79% of slide height; the lower teal segment (#008378-like teal) fills roughly the lower three-quarters and the upper segment is dark navy #0C2340; the teal segment is labelled '~70%' in white bold near its centre; no axis units or ranges printed. Caption beneath the bar: 'Mid 2030s revenue opportunity from potential new growth drivers' with superscript 1. A teal-to-transparent gradient wedge connects the top and bottom corners of the bar to the grey panel edges (a zoom/callout effect). Right panel: 12 tiles in a grid with three columns (x about 38%, 56.7%, 75.1%) and four rows (y about 28.9%, 42.8%, 56.7%, 71%) plus MK-3000 in the middle column at y 85%. Tiles colour-coded by category: Cardiometabolic & Respiratory tiles lavender #DDDCFA with a #5350E4 left bar (WINREVAIR logo, Ohtuvayre logo, enlicitide decanoate); Infectious Disease tiles pale blue #E1F1FD with a #69B8F7 left bar (MK-1406, islatravir based QW regimens, ENFLONSIA logo, MK-3000 in yellow); Oncology/Immunology tiles mint #E2F5F0 with #6ECEB2 left bar (ifinatamab deruxtecan, sacituzumab tirumotecan); Immunology tile pale lime #F2FBD6 with #BFED33 left bar (tulisokibart); MK-3000 yellow #FFF9C1 with #FFF063 left bar. Logos: WINREVAIR wordmark in bold navy-blue italic caps with a multicolour swoosh above it and a small grey text line; Ohtuvayre wordmark in navy lowercase with a blue wave over the 'v', with '(ensifentrine) Inhalation Suspension' and a cyan '3 mg/2.5 mL' tag; ENFLONSIA wordmark in dark green spaced capitals with a green leaf-like emblem above and '(clesrovimab-cfor) 105 mg injection' below. Bottom-right small teal two-tone circular logo mark (corporate icon).
Slide 13
By 2026, clinically derisked revenue opportunity nearly offsets
KEYTRUDA LOE
>$70B
~$35B
Consensus 2028
total KEYTRUDA
sales1,2
Mid 2030s revenue
opportunity from
potential new growth
drivers3
2028+
2027
2026
Today
Increasingly clinically derisked4
Additional innovative pipeline programs
sacituzumab
tirumotecan5
MK-1406
ifinatamab
deruxtecan6
islatravir /
lenacapavir7
MK-3000
tulisokibart
WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg
Ohtuvayre (ensifentrine) inhalation suspension 3 mg/2.5 mL
ENFLONSIA (clesrovimab-cfor) 105 mg injection
enlicitide
decanoate
1. Total KEYTRUDA sales include KEYTRUDA and KEYTRUDA QLEX 2. Source: Evaluate Pharma consensus estimate as of January 2026 3. Non-risk adjusted annual sales by the mid 2030s 4. Clinically
derisked figures include total mid-2030s commercial opportunity for a compound upon first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 5. In collaboration with Kelun
Biotech 6. In collaboration with Daiichi Sankyo 7. In collaboration with Gilead
13
Visuals: Chart: stacked bar chart drawn as an image with transparent background. Left bar is a single solid navy #0C2340 column, x about 9.5% to 24.5% of slide width, top at about 50.2% and base at about 75.8% of slide height, labelled above as ~$35B, captioned Consensus 2028 total KEYTRUDA sales (superscript 1,2). Right bar is a stacked column, x about 35.1% to 50.2%, top at about 28.1% and base at about 75.8%, labelled above as >$70B. Its segments from bottom to top are: Today, teal #00857C, about 62.5% to 75.8% height; 2026, mint #6ECEB2, about 51.5% to 62.5%; 2027, periwinkle blue #688CE8, about 34.9% to 51.5%; 2028+, light sky blue #69B8F7, about 28.1% to 34.9%. Segment labels are white bold text centred in each segment. Caption below reads Mid 2030s revenue opportunity from potential new growth drivers (superscript 3). Dashed grey #BFBFBF line runs horizontally from the top of the navy bar to the stacked bar at about 50.3% height. Axis: a thin navy #0C2340 horizontal line from about x 4.2% to 55.5% at about 75.8% height, with small vertical tick marks at x 4.2%, 29.8% and 55.5%. No numeric axis, no y-axis, no legend (segments are labelled directly). Arrow: a solid light grey #D9D9D9 upward block arrow at x 50.7% to 57.1%, y 26.2% to 75.5%, with a rotated navy bold label reading Increasingly clinically derisked (superscript 4) running upward inside its shaft. Pipeline: three rows of names in colour (#688CE8 row 1, #6ECEB2 row 2) with superscript footnote numbers, and enlicitide decanoate in #00857C. Logos (left to right): WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg wordmark in navy and purple-blue with a small red-blue swoosh; Ohtuvayre (ensifentrine) inhalation suspension, 3 mg/2.5 mL, navy wordmark with blue swoosh and a small light blue label; ENFLONSIA (clesrovimab-cfor) 105 mg injection, dark green wordmark with a green leaf icon above; enlicitide decanoate in bold teal text. Corner logo: small dark teal four-lobed mark at bottom right, about 91.8% to 94.9% x and 92.8% to 99.4% y. No photographs.
Slide 14
Data-rich period ahead with multiple Phase 3 readouts across novel mechanisms
2026
ISL / LEN1
MK-3000
tulisokibart
Mechanism of action
Nucleoside reverse transcriptase translocation inhibitor / capsid inhibitor
Wnt agonist
TL1A mAb
Therapeutic area
HIV
Ophthalmology
Immunology
Disease area
Treatment (oral, QW)
Diabetic macular edema
Ulcerative colitis
Phase 3 study PCD
ISLEND-1 and ISLEND-2 Apr 2026
BRUNELLO Sept 2026 (BAROLO Mar 2027)
ATLAS-UC Aug 2026
1. In collaboration with Gilead
14
Visuals: A table with no chart elements. Header row 1: a single merged teal bar labelled 2026 spanning the three data columns. Header row 2: three teal cells labelled ISL / LEN with superscript 1, MK-3000, and tulisokibart. Row labels in navy cells (left column): Mechanism of action; Therapeutic area; Disease area; Phase 3 study PCD. Data cells: Mechanism of action: ISL / LEN = Nucleoside reverse transcriptase translocation inhibitor / capsid inhibitor; MK-3000 = Wnt agonist; tulisokibart = TL1A mAb. Therapeutic area: HIV; Ophthalmology; Immunology. Disease area: Treatment (oral, QW); Diabetic macular edema; Ulcerative colitis. Phase 3 study PCD: ISLEND-1 and ISLEND-2 Apr 2026; BRUNELLO Sept 2026 (BAROLO Mar 2027); ATLAS-UC Aug 2026. One small teal four-lobed logo at bottom right, no photographs or icons.
Slide 15
Data-rich period ahead with multiple Phase 3 readouts across novel
mechanisms
2026
2027
ISL / LEN1
MK-3000
tulisokibart
sac-TMT2
MK-1406
I-DXd3
Mechanism of
action
Nucleoside
reverse
transcriptase
translocation
inhibitor / capsid
inhibitor
Wnt agonist
TL1A mAb
TROP2 ADC
zanamivir-Fc
conjugate
B7H3 ADC
Therapeutic
area
HIV
Ophthalmology
Immunology
Oncology
Infectious
Disease
Oncology
Disease
area
Treatment
(oral, QW)
Diabetic macular
edema
Ulcerative
colitis
Various tumor
types
Influenza
Various tumor
types
Phase 3 study
PCD
ISLEND-1 and
ISLEND-2
Apr 2026
BRUNELLO
Sept 2026
(BAROLO Mar 2027)
ATLAS-UC
Aug 2026
TroFuse
(16 Phase 3 studies;
PCDs beginning in
2027)
ANCHOR
Jan 2027
IDeate
(3 Phase 3 studies;
PCDs beginning in
2027)
1. In collaboration with Gilead 2. In collaboration with Kelun Biotech 3. In collaboration with Daiichi Sankyo
15
Visuals: No chart, photograph or diagram. A table of 6 product columns in two year groups and 4 rows. Column headers: 2026 group (spanning ISL / LEN1, MK-3000, tulisokibart) on a mint band; 2027 group (spanning sac-TMT2, MK-1406, I-DXd3) on a periwinkle band. Row labels: Mechanism of action; Therapeutic area; Disease area; Phase 3 study PCD. Cell values: ISL / LEN1 mechanism Nucleoside reverse transcriptase translocation inhibitor / capsid inhibitor; therapeutic area HIV; disease area Treatment (oral, QW); study ISLEND-1 and ISLEND-2 Apr 2026. MK-3000 mechanism Wnt agonist; area Ophthalmology; disease Diabetic macular edema; study BRUNELLO Sept 2026 (BAROLO Mar 2027). tulisokibart mechanism TL1A mAb; area Immunology; disease Ulcerative colitis; study ATLAS-UC Aug 2026. sac-TMT2 mechanism TROP2 ADC; area Oncology; disease Various tumor types; study TroFuse (16 Phase 3 studies; PCDs beginning in 2027). MK-1406 mechanism zanamivir-Fc conjugate; area Infectious Disease; disease Influenza; study ANCHOR Jan 2027. I-DXd3 mechanism B7H3 ADC; area Oncology; disease Various tumor types; study IDeate (3 Phase 3 studies; PCDs beginning in 2027). Small teal logo mark bottom-right: a four-lobed rounded teal emblem, about 3% wide.
Slide 16
Delivering pipeline advancement and portfolio transformation
Executing on Strategic / Priorities
Entering Data-Rich / Period
Delivering on / Our Purpose
Successful acceleration and / augmentation of pipeline has / yielded >20 potential new / growth drivers
Anticipating multiple / impactful Phase 3 readouts / through 2027
Advance leading-edge / science to save and improve / lives and create long-term / value for patients and / shareholders
16
Visuals: Three line icons in outline style, each about 10% of slide width. Left: a teal #00857C target/crosshair (concentric circles with crosshair ticks) overlapped by a teal chess pawn at its lower right, stroke about 0.3% of slide height. Centre: a mint #6ECEB2 dashboard panel with a rounded-corner frame containing a dotted-line chart with node markers at top left, a list icon at top right, a bar chart with three vertical bars at lower right and a pie chart with one wedge split at lower left. Right: a blue #688CE8 open hand palm-up with three connected circular nodes above it (two small circles and one larger circle at top right) linked by straight lines. No photographs. Three thin dotted grey (#BFC5CC) vertical dividers run from about y 44% to y 80%, one at x about 34.1% and one at x about 65.7%.
Slide 17
Q&A / Rob Davis / Chairman and Chief Executive Officer / Dr. Dean Li / President, Merck Research Laboratories
Visuals: 1) Logo: a teal four-lobed mark made of rounded petals with a horizontal white split through the middle, in #00857C, at the top-left corner. 2) Photograph (right half, x 50 to 100%, y 0 to 88.9%, hard-edged rectangle, full-bleed to the top and right edges): an audience in a bright, blurred lobby with several hands raised. In the foreground, a woman with dense curly reddish-brown hair faces away from the camera, and her right arm is raised with a dark patterned blue long-sleeved shirt, a wooden bead bracelet and hoop earrings. Other raised hands, a woman in a black top and a man in a white shirt are blurred in the background. Ceiling lights appear as soft bokeh strings near the top. Composition is shallow depth of field with the subject in the lower-centre; lighting is soft, warm and natural; dominant colours are warm beige, brown, cream and deep navy. 3) Headshot of Rob Davis (x 3.1%, y 58.7%, 8.0% by 14.3%, boxed square-cornered rectangle): a smiling bald man with rectangular dark-framed glasses, navy suit, white shirt and purple tie, against a mid-grey studio backdrop, head and shoulders framed, lit evenly from the front. 4) Headshot of Dr. Dean Li (x 3.1%, y 74.6%, 8.1% by 14.3%, boxed square-cornered rectangle): a smiling man with short hair, dark-framed glasses, light grey suit, white shirt and patterned tie, against a mid-grey studio backdrop, head and shoulders framed, lit evenly from the front. 5) Grey panel #D9D9D9 (x 50%, y 0%, 50% by 88.9%) sits directly behind the photograph and is hidden by it.
Slide 18
Appendix
Visuals: A small teal logo mark in the bottom-right corner, consisting of four rounded lobes arranged around a centre in a clover-like pattern, about 3% of slide width. No photographs, charts or other graphics.
Slide 19
Strategic business development drives increase in mid-2030s commercial opportunity / Prior Opportunity1 / Updated Opportunity1 / Oncology / >$25B / >$25B / Cardiometabolic & Respiratory / ~$15B / ~$20B2 / Infectious Disease / >$5B / ~$15B3 / Immunology / >$5B / >$5B / Ophthalmology / Multibillion / >$5B / Amounts above exclude currently marketed products (except WINREVAIR, OHTUVAYRE, CAPVAXIVE and ENFLONSIA), early-phase programs and additional business development / 1. Non-risk adjusted annual sales by the mid 2030s 2. Now includes OHTUVAYRE 3. Now includes MK-1406, ENFLONSIA, V181 / 19
Visuals: Comparison table-style diagram with five rows. Row 1 Oncology: label bar teal #00857C with white bold text; prior value >$25B in grey #7F7F7F on #F2F2F2 cell; a horizontal arrow fading from white at its tail to teal #00857C at its head pointing right; updated value >$25B in teal #00857C on pale mint #E2F5F0 cell. Row 2 Cardiometabolic & Respiratory: label bar indigo #5350E4 with white bold two-line text; prior ~$15B grey on #F2F2F2; arrow fading from white to indigo #5350E4; updated ~$20B with superscript 2 in indigo #5350E4 on pale lavender #DDDCFA. Row 3 Infectious Disease: label bar sky blue #69B8F7 with white bold text; prior >$5B grey on #F2F2F2; arrow fading from white to sky blue #69B8F7; updated ~$15B with superscript 3 in sky blue #69B8F7 on pale blue #E1F1FD. Row 4 Immunology: label bar lime #BFED33 with white bold text; prior >$5B grey on #F2F2F2; arrow fading from white to lime #BFED33; updated >$5B in olive-green #9AC612 on pale lime #F2FBD6. Row 5 Ophthalmology: label bar yellow #FFF063 with white bold text; prior Multibillion grey on #F2F2F2; arrow fading from white to yellow #FFF063; updated >$5B in dark gold #B1A000 on pale yellow #FFFCE0. Dotted light grey row separators run between rows. Small teal logo mark at bottom right (a rounded teal pill-and-circle emblem, two stacked teal shapes, colour #00857C), no other logos or photographs.
Slide 20
Robust pipeline to drive patient impact and value creation into the mid-2030s / Updated Opportunity1 / Additional Opportunities / Oncology / >$25B / Cardiometabolic & Respiratory / ~$20B / Infectious Disease / ~$15B / Immunology / >$5B / Ophthalmology / >$5B / Animal Health / Expect revenue to more than double by the mid-2030s2 / Early-Phase Programs / Many advancing to Phase 2 in near-term / Business Development / Significant capacity to further augment pipeline / Amounts above exclude currently marketed products (except WINREVAIR, OHTUVAYRE, CAPVAXIVE and ENFLONSIA), early-phase programs and additional business development / 1. Non-risk adjusted annual sales by the mid 2030s 2. Expected to double off of 2024 baseline revenue / 20
Visuals: Five coloured horizontal label boxes stacked down the left, each with a centred white bold label: Oncology (teal), Cardiometabolic & Respiratory (violet), Infectious Disease (sky blue), Immunology (lime), Ophthalmology (yellow). Beside each sits a pale tinted value box with a centred bold value in the label colour: >$25B (teal on mint), ~$20B (violet on lavender), ~$15B (sky blue on pale blue), >$5B (lime-green on pale lime), >$5B (olive-gold on pale yellow). Thin light grey dotted separators run between rows. A large navy plus sign sits between the two columns, its vertical bar centred near x 55% and its horizontal bar spanning about x 49.8 to 60.8%, with a small white notch cut at its left edge beside the ~$15B value box. The right grey panel contains three navy horizontal rules and three line icons: a navy line drawing of a dog and a cat at about x 61 to 68%, y 33 to 45%, beside Animal Health; a navy map pin with a rising arrow line joined by three small circles at about x 61 to 69%, y 55 to 66%, beside Early-Phase Programs; and a navy lightbulb with a double chevron inside and radiating rays at about x 61 to 67%, y 72 to 85%, beside Business Development. A teal four-lobed corporate logo sits at bottom right (x 91.8, y 92.8%). No chart or table is present.
Slide 21
More than 20 new growth drivers expected in the next several years, almost all of which have blockbuster potential
2024
2025
2026
2027
2028+
WINREVAIR (sotatercept-csrk) for injection 45 mg/60 mg
★
Ohtuvayre (ensifentrine) Inhalation Suspension 3 mg/2.5 mL
★
CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine
KEYTRUDA Qlex pembrolizumab + berahyaluronidase alfa-pmph
ENFLONSIA (clesrovimab-cfor) 105 mg injection
★
enlicitide decanoate
Oral PCSK9i
★
doravirine + islatravir
NNRTI + NRTTI
islatravir + lenacapavir²
NRTTI + capsid inhibitor
★
MK-3000
Wnt agonist
★
tulisokibart
TL1A mAb
★
MK-1406
zanamivir-Fc conjugate
★
sacituzumab tirumotecan²
TROP2 ADC
★
ifinatamab deruxtecan²
B7-H3 ADC
★
nemtabrutinib
BTKi
MK-8527
NRTTI
zilovertamab vedotin
ROR1 ADC
raludotatug deruxtecan²
CDH6 ADC
bomedemstat
LSD1i
intismeran autogene²
INT
opevesostat
CYP11A1i
calderasib²
KRAS G12Ci
patritumab deruxtecan²
HER3 ADC
V181
Tetravalent dengue vaccine
gocatamig
DLL3 T-cell engager
MK-1045
CD3xCD19 T-cell engager
MK-8748
Tie2 agonist/VEGFi
islatravir + ulonivirine
NRTTI + NNRTI
Key near-term programs
First-in-class potential
Therapeutic area
Oncology
Cardiometabolic & Respiratory
Infectious Disease
Immunology
Ophthalmology
Mid-2030s commercial opportunity³
>$25B¹
~$20B
~$15B
>$5B
>$5B
Timing above represents approval date for marketed products or earliest Phase 3 primary completion date according to clinicaltrials.gov for pipeline compounds
1. Excludes KEYTRUDA QLEX 2. Being developed in collaboration 3. Non-risk adjusted annual sales by the mid 2030s
21
Visuals: Timeline diagram with five gray chevron arrows labelled 2024, 2025, 2026, 2027 and 2028+ across the top. Under each year are rounded rectangular cards, each with a coloured border and left accent bar keyed to therapeutic area: Winrevair, Ohtuvayre and Capvaxive logos in 2024; Keytruda Qlex, Enflonsia, enlicitide decanoate and doravirine + islatravir in 2025; islatravir + lenacapavir, MK-3000 and tulisokibart in 2026; MK-1406, sacituzumab tirumotecan, ifinatamab deruxtecan, nemtabrutinib, MK-8527, zilovertamab vedotin, raludotatug deruxtecan and bomedemstat in 2027; intismeran autogene, opevesostat, calderasib, patritumab deruxtecan, V181, gocatamig, MK-1045, MK-8748 and islatravir + ulonivirine in 2028+. Nine cards carry a navy filled five-point star at their right edge (Winrevair, Ohtuvayre, Enflonsia, enlicitide decanoate, islatravir + lenacapavir, MK-3000, tulisokibart, sacituzumab tirumotecan, ifinatamab deruxtecan). Legend: navy star = Key near-term programs; grey vertical bar = First-in-class potential. Bottom table: header row of five colour-coded boxes (Oncology mint, Cardiometabolic & Respiratory lavender, Infectious Disease light blue, Immunology pale green, Ophthalmology pale yellow) and a value row of five light grey cells reading >$25B¹, ~$20B, ~$15B, >$5B, >$5B. Logos: WINREVAIR, Ohtuvayre, CAPVAXIVE, KEYTRUDA Qlex, ENFLONSIA, and a small teal Merck-style mark bottom right. No photographs.
Slide 22
Acronyms
ADC = Antibody-drug conjugate
B7H3 = B7 homolog 3
BRVO = Branch retinal vein occlusion
BTKi = Bruton tyrosine kinase inhibitor
CD3 = Cluster of differentiation 3
CD19 = Cluster of differentiation 19
CDH6 = Cadherin-6
COPD = Chronic obstructive pulmonary disease
CRC = Colorectal cancer
CYP11A1 = Cytochrome P450 family 11 subfamily A member 1
DLL3 = Delta-like ligand 3
DME = Diabetic macular edema
Fc = Fragment crystallizable
HeFH = Heterozygous familial hypercholesterolemia
HER3 = Human epidermal growth factor receptor 3
IBD = Inflammatory bowel disease
I-DXd = Ifinatamab deruxtecan
INT = Individualized neoantigen therapy
ISL/LEN = Islatravir / lenacapavir
KRAS = Kirsten rat sarcoma viral oncogene homolog
LA HNSCC = Locally advance head and neck squamous cell carcinoma
LOE = Loss of exclusivity
Lp(a) = Lipoprotein(a)
LSD1i = Lysine-specific demethylase 1 inhibitor
mAb = Monoclonal antibody
mCRPC = Metastatic castration-resistant prostate cancer
MIBC = Muscle invasive bladder cancer
NNRTI = Non-nucleoside reverse transcriptase inhibitor
NRTTI = Nucleoside reverse transcriptase translocation inhibitor
NSCLC = Non-small cell lung cancer
NVAMD = Neovascular age-related macular degeneration
PAH = Pulmonary arterial hypertension
PCSK9 = Proprotein convertase subtilisin/kexin type 9
P-DXd = Patritumab deruxtecan
PrEP = Pre-exposure prophylaxis
PROC = Platinum resistant ovarian cancer
QW = Once weekly
RCC = Renal cell carcinoma
ROR1 = Receptor tyrosine kinase-like orphan receptor 1
RSV = Respiratory syncytial virus
sac-TMT = Sacituzumab tirumotecan
TL1A = Tumor necrosis factor-like ligand 1A
Tie2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2
TROP2 = Trophoblast cell surface antigen-2
UC = Ulcerative colitis
VEGF = Vascular endothelial growth factor
Wnt = Wingless-related integration site
22
Visuals: Teal four-lobed logo mark at bottom right, about 125 by 150 pixels, placed at x 91.8%, y 92.8%, 3.1% by 6.6% of the slide. No charts, photographs or other illustrations.
Download this deck
The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.
Building a deck of your own? The SlideDeck Co Standard Deck is a slide library for business presentations: reviews, updates and plans.






